This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Surgery  • Surgery, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Carlos Alberto Ramirez Alvarado, MD; Selwyn M. Vickers, MD
Birmingham, Ala

Arch Surg. 2001;136:69.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

This prospective, controlled, single-arm study represents a valuable effort in justifying the need of adjuvant treatment in patients with ampullary carcinoma. Since the studies of the Gastrointestinal Study Group (GITSG), we have seen a significant increase in the use of adjuvant treatment for periampullary carcinomas, albeit with conflicting results. Although the 89% actuarial overall survival reported by Mehta et al is one of the highest reported, these data should be considered with caution, because of the small number of patients with limited follow-up. It should be noted that the median survival has not been reached in this group of patients due to limited follow-up and 3 deaths, although the authors reported the median survival to be 34 months. In addition, the authors compared these results with those of patients diagnosed as having pancreatic cancer; thus, one would expect to see differences . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Adjuvant Chemoradiotherapy for "Unfavorable" Carcinoma of the Ampulla of Vater: Preliminary Report
Vivek K. Mehta, George A. Fisher, James M. Ford, Joseph C. Poen, Mark A. Vierra, Harry A. Oberhelman, and Augusto J. Bastidas
Arch Surg. 2001;136(1):65-69.
ABSTRACT | FULL TEXT